ARISTADA INITIO

Serial Number 87276061
Registration 5581432
702

Registration Progress

Application Filed
Dec 21, 2016
Under Examination
Apr 18, 2017
Approved for Publication
Feb 21, 2017
Published for Opposition
Feb 21, 2017
Registered
Oct 9, 2018

Trademark Image

ARISTADA INITIO

Basic Information

Serial Number
87276061
Registration Number
5581432
Filing Date
December 21, 2016
Registration Date
October 9, 2018
Published for Opposition
February 21, 2017
Drawing Code
4000

Status Summary

Current Status
Active
Status Code
702
Status Date
Apr 8, 2024
Registration
Registered
Classes
005

Rights Holder

Alkermes Pharma Ireland Limited

03
Address
1 BURLINGTON ROAD
CONNAUGHT HOUSE
DUBLIN 4
IE

Ownership History

Alkermes Pharma Ireland Limited

Original Applicant
03
DUBLIN 4 IE

Alkermes Pharma Ireland Limited

Owner at Publication
03
DUBLIN 4 IE

Alkermes Pharma Ireland Limited

Original Registrant
03
DUBLIN 4 IE

Legal Representation

Attorney
Norm J. Rich

USPTO Deadlines

Next Deadline
1164 days remaining
Section 8 & 9 (10-Year) Renewal Due (Based on registration date 2018-10-09)
Due Date
October 09, 2028
Grace Period Ends
April 09, 2029

Application History

28 events
Date Code Type Description Documents
Apr 8, 2024 APRE A CASE ASSIGNED TO POST REGISTRATION PARALEGAL Loading...
Apr 8, 2024 C15A O REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK. Loading...
Apr 8, 2024 NA85 E NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED Loading...
Oct 11, 2023 E815 I TEAS SECTION 8 & 15 RECEIVED Loading...
Oct 9, 2023 REM1 E COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED Loading...
Oct 9, 2018 R.PR A REGISTERED-PRINCIPAL REGISTER Loading...
Sep 4, 2018 SUNA E NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED Loading...
Sep 1, 2018 CNPR P ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED Loading...
Aug 16, 2018 SUPC I STATEMENT OF USE PROCESSING COMPLETE Loading...
Aug 14, 2018 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL Loading...
Jul 18, 2018 EISU I TEAS STATEMENT OF USE RECEIVED Loading...
Jul 18, 2018 IUAF S USE AMENDMENT FILED Loading...
Jan 26, 2018 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Jan 24, 2018 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Jan 24, 2018 EXT2 S SOU EXTENSION 2 FILED Loading...
Jan 24, 2018 EX2G S SOU EXTENSION 2 GRANTED Loading...
Sep 8, 2017 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Sep 6, 2017 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Sep 6, 2017 EXT1 S SOU EXTENSION 1 FILED Loading...
Sep 6, 2017 EX1G S SOU EXTENSION 1 GRANTED Loading...
Apr 18, 2017 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Feb 21, 2017 PUBO A PUBLISHED FOR OPPOSITION Loading...
Feb 21, 2017 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Feb 1, 2017 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Jan 16, 2017 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Jan 10, 2017 DOCK D ASSIGNED TO EXAMINER Loading...
Jan 3, 2017 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Dec 24, 2016 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Pharmaceuticals, namely, prodrugs and chemical derivatives of pharmaceutically active ingredients for the treatment of central nervous system diseases and disorders, psychiatric and neurodegenerative diseases, cardiovascular diseases and metabolic diseases; Pharmaceutical compounds, namely, prodrugs and chemical derivatives of pharmaceutically active ingredients for the treatment of central nervous system diseases and disorders, psychiatric and neurodegenerative diseases, cardiovascular diseases and metabolic diseases
First Use Anywhere: Jul 16, 2018
First Use in Commerce: Jul 16, 2018

Classification

International Classes
005